In high- risk populations, intermittent AFP serum levels and liver ultrasounds are utilized as surveillance strategies, but as HCC is detected at a localized stage in fewer than 50% of cases, there remains a need for more reliable screenings (https://www.cancer.gov/types/liver/patient/liver-screening-pdq; accessed 2017). This evidence concerns the gene AFP and hepatocellular carcinoma.